NeuroThrive - Dementia Prevention (Brooke Allen, MD - Board Certified Neurologist)
- $750 Regular Price
- $600 for NeuroSpa Beauty Bank Members
Did you know that modifiable risk factors for dementia are most effective when addressed and optimized in mid-life or sooner? This offering is for those looking to be proactive in preventing dementia of any kind.
Dementia prevention isn’t about a single intervention, but a multifactorial approach. Research shows that up to 40% of dementia cases may be preventable through addressing modifiable risk factors, especially in midlife.
Included in Your Appointment:
- Dementia Risk Factor Assessment and Counseling
- Medication/Supplement Review and Counseling
- Family History Review
- Substance Use Review
- Mental Health Assessment
- Lifestyle Review (Exercise, Sleep, Relationships, Stress Management, Lifelong Learning, Mindfulness, Nutrition, Purpose, and Service)
- Lab Review
- Discussion: Memory and Neuropsychological Testing
- Discussion: Genetic Testing
- Discussion: Alzheimer’s Blood Based Biomarker Testing
- Monthly Correspondence from Dr. Allen on the latest research in Brain Health and Optimization
Prior to your appointment date, you will receive a few questionnaires to complete to help get the conversation started.
Must have ZOOM capability to schedule.
CLINICAL RESEARCH FOR DEMENTIA
Our team of medical professionals collaborates with Mountain Neurological Research Center to bring dementia prevention and treatment options to the Roaring Fork Valley. We specialize in late-stage clinical trials required by the FDA - the final, critical steps before a new therapy can reach the people who need it most. If you or your loved one are interested in being part of our research community and advancing a cure towards Alzheimer's disease and other types of dementia, please reach out to our Lead Clinical Trial Coordinator, Catherine Vasquez at catherine@rfneurology.com.
UNDERSTANDING CLINICAL RESEARCH TRIALS
CLINICAL TRIALS CURRENTLY ENROLLING
About the Buntanetap Trial Sponsored by Annovis Bio, Inc.
WHO is this trial for?
This trial is enrolling adults with early Alzheimer's disease whose diagnosis has been confirmed through biomarker testing. The goal is to enroll approximately 760 participants across roughly 100 research sites throughout the United States (Annovisbio). If you or someone you love has received an early Alzheimer's diagnosis, this study may be worth exploring.
WHAT is being studied?
Buntanetap is a small, orally available pill that targets neurodegeneration by blocking the production of neurotoxic proteins — the harmful substances that damage brain cells in Alzheimer's disease. By interrupting this toxic process, buntanetap works to improve communication between nerve cells, reduce brain inflammation, and potentially restore healthy brain function. In simpler terms, it is designed not only to ease symptoms, but to address the underlying damage that Alzheimer's causes.
WHEN will we know if it works?
The trial has a two-part design: an initial 6-month period to evaluate whether buntanetap improves symptoms, followed by an additional 12 months to assess whether it may actually slow the progression of the disease. The first group of patients has already completed the 6-month treatment period, and symptomatic results are expected in the second half of 2026.
About the MINDSET Study
Sponsored by Bristol Myers Squibb
WHO is this trial for?
The MINDSET trials are enrolling adults with mild to moderate Alzheimer's dementia whose diagnosis has been confirmed through biomarker testing. If you or someone you love has received a mild to moderate Alzheimer's diagnosis, this study may be an option worth exploring. A caregiver or study partner will also be an important part of participation.
WHAT is being studied?
MINDSET is testing an oral pill (also known as xanomeline-trospium), that works by stimulating specific receptors in the brain — called muscarinic receptors — that play a key role in memory and thinking. The decline of cholinergic function in Alzheimer's disease is closely tied to cognitive symptoms, and the trial medication's approach to activating these receptors may help improve cognition while also reducing the confusion and agitation that so often accompany the disease. Xanomeline-trospium is already FDA-approved for the treatment of schizophrenia, and this research explores whether it can do the same for the thinking and memory problems caused by Alzheimer's.
WHEN will we know if it works?
MINDSET-1 and MINDSET-2 each have a 24-week placebo-controlled treatment period and are running at more than 100 locations across 21 countries, with trials expected to conclude in September 2028. The primary measures being tracked include changes in cognitive test scores and a clinician's overall assessment of how participants are functioning day to day — two of the most meaningful markers of real-world improvement.
About the CorEvitas Alzheimer's Drug Safety and Effectiveness Registry
Sponsored by CorEvitas, LLC in partnership with PPD and Thermo Fisher Scientific
WHO is this registry for?
This registry is open to adults who have been diagnosed with mild cognitive impairment (MCI), early Alzheimer's disease, Alzheimer's disease, or dementia where Alzheimer's is suspected. To participate, you must be currently prescribed — and planning to start — an FDA-approved medication for Alzheimer's disease or its symptoms. A care partner, such as a family member or close friend who spends at least ten hours a week with you, will also be an important part of your participation. The registry aims to enroll approximately 2,000 participants across roughly 75 clinical sites worldwide.
WHAT is being studied?
This is not a drug trial — no experimental treatments are involved. Instead, this is a real-world observational registry designed to track how approved Alzheimer's medications — including newer amyloid-targeting therapies like Leqembi (lecanemab) and Kisunla (donanemab), as well as longer-standing medications like Aricept and Namenda — perform in everyday clinical settings outside of controlled research conditions. Your care team will continue making all treatment decisions exactly as they would without the registry. The study simply observes and records how things go: how you respond to your medication, how your daily functioning changes over time, and whether any safety concerns arise. Brain imaging results will also be tracked for participants receiving amyloid-targeting therapies, to monitor for a condition called ARIA — a known risk with that class of treatment that requires careful watching.
WHEN does participation take place?
The registry has no fixed end date — it is designed to follow participants for as long as their care continues and they wish to remain enrolled. After an initial enrollment visit, you would check in approximately every six months, timed to coincide with your regular medical appointments so that participation fits naturally into your existing care routine. There is no extra travel or procedures required beyond what your doctor is already doing.
WHY does this registry matter?
Clinical trials tell us whether a treatment works in a controlled setting. What they often can't tell us is how those same treatments perform in the real world — in people with different health histories, taking other medications, living real lives. That gap in knowledge is exactly what this registry is designed to fill. As newer Alzheimer's therapies reach more and more patients, it is critical that researchers, doctors, and regulators understand their long-term safety and effectiveness in the broader population. Your participation helps build that picture — and every data point you contribute helps make Alzheimer's care safer and smarter for everyone who comes after you.
